Literature DB >> 24138643

Ethical, legal and social implications of rare diseases and orphan drugs in Europe: meeting report of a Brocher symposium.

Eline Picavet1, David Cassiman, Wim Pinxten, Steven Simoens.   

Abstract

Ethical, legal and social implications of rare diseases and orphan drugs in Europe (Brocher symposium) Geneva, Switzerland 18-19 April 2013 As part of the Scientific Program of the Fondation Brocher, a two-day symposium on orphan drugs and rare diseases was held on the shores of Lac Léman in Geneva. Specific focus was on the ethical, legal and social implications of rare diseases and orphan drugs in Europe. The symposium gathered about 30 international stakeholders and experts, representing different scientific disciplines, the pharmaceutical industry and patient representatives.

Entities:  

Mesh:

Year:  2013        PMID: 24138643     DOI: 10.1586/14737167.2013.832626

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  5 in total

1.  Ethical Questions Linked to Rare Diseases and Orphan Drugs - A Systematic Review.

Authors:  Jaroslav Kacetl; Petra Marešová; Raihan Maskuriy; Ali Selamat
Journal:  Risk Manag Healthc Policy       Date:  2020-10-13

Review 2.  How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.

Authors:  Alessandra Blonda; Yvonne Denier; Isabelle Huys; Steven Simoens
Journal:  Front Pharmacol       Date:  2021-05-12       Impact factor: 5.810

Review 3.  A systematic review of moral reasons on orphan drug reimbursement.

Authors:  Bettina M Zimmermann; Johanna Eichinger; Matthias R Baumgartner
Journal:  Orphanet J Rare Dis       Date:  2021-06-30       Impact factor: 4.123

Review 4.  Using a meta-narrative literature review and focus groups with key stakeholders to identify perceived challenges and solutions for generating robust evidence on the effectiveness of treatments for rare diseases.

Authors:  Kylie Tingley; Doug Coyle; Ian D Graham; Lindsey Sikora; Pranesh Chakraborty; Kumanan Wilson; John J Mitchell; Sylvia Stockler-Ipsiroglu; Beth K Potter
Journal:  Orphanet J Rare Dis       Date:  2018-06-28       Impact factor: 4.123

5.  How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries.

Authors:  Alessandra Blonda; Yvonne Denier; Isabelle Huys; Pawel Kawalec; Steven Simoens
Journal:  Front Pharmacol       Date:  2022-07-19       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.